首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL23p19 |
| Uniprot No | Q9NPF7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-328aa |
| 氨基酸序列 | IWELKKDVYV VELDWYPDAP GEMVVLTCDT PEEDGITWTL DQSSEVLGSG KTLTIQVKEF GDAGQYTCHK GGEVLSHSLL LLHKKEDGIW STDILKDQKE PKNKTFLRCE AKNYSGRFTC WWLTTISTDL TFSVKSSRGS SDPQGVTCGA ATLSAERVRG DNKEYEYSVE CQEDSACPAA EESLPIEVMV DAVHKLKYEN YTSSFFIRDI IKPDPPKNLQ LKPLKNSRQV EVSWEYPDTW STPHSYFSLT FCVQVQGKSK REKKDRVFTD KTSATVICRK NASISVRAQD RYYSSSWSEW ASVPCSGSTS GSGKPGSGEG STKGRAVPGG SSPAWTQCQQ LSQKLCTLAW SAHPLVGHMD LREEGDEETT NDVPHIQCGD GCDPQGLRDN SQFCLQRIHQ GLIFYEKLLG SDIFTGEPSL LPDSPVGQLH ASLLGLSQLL QPEGHHWETQ QIPSLSPSQP WQRLLLRFKI LRSLQAFVAV AARVFAHGAA TLSP |
| 预测分子量 | 70 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL23p19重组蛋白的3篇代表性文献(简略版)：
1. **文献名称**：*Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain*
**作者**：Cua, D.J., et al.
**摘要**：首次阐明IL-23(由IL23p19和IL12p40组成)通过驱动Th17细胞分化，在自身免疫性疾病中的核心作用，为靶向IL23p19的疗法奠定理论基础。
2. **文献名称**：*Structural basis of receptor sharing by interleukin 12 and interleukin 23*
**作者**：Yoon, S.I., et al.
**摘要**：通过X射线晶体学解析IL-23(含IL23p19)与其受体的结合结构，揭示其与IL-12共享IL12Rβ1的分子机制，为设计特异性抑制剂提供结构依据。
3. **文献名称**：*Efficient production of human IL-23 using novel chaperone in Escherichia coli*
**作者**：Lee, J.S., et al.
**摘要**：开发了一种基于大肠杆菌的重组IL-23高效表达系统，通过分子伴侣共表达策略解决IL23p19/p40异源二聚体折叠难题，提升蛋白产量与稳定性。
4. **文献名称**：*Targeting IL-23p19 for immune-mediated diseases: current advances and future perspectives*
**作者**：Benson, J.M., et al.
**摘要**：综述IL23p19在银屑病、克罗恩病等疾病中的病理机制，总结单抗类药物(如risankizumab)的临床前及临床研究进展，强调重组蛋白技术的治疗潜力。
(注：以上为示例性内容，实际文献需通过PubMed等数据库核对详细信息。)
Interleukin-23 (IL-23) is a pro-inflammatory cytokine critical in mediating immune responses, particularly in autoimmune and chronic inflammatory diseases. It is a heterodimeric protein composed of two subunits: p19 (IL-23α) and p40. the latter shared with IL-12. The p19 subunit is unique to IL-23 and determines its biological specificity. Recombinant IL-23p19 protein refers to the isolated p19 subunit produced via genetic engineering, often using mammalian (e.g., CHO) or bacterial (e.g., E. coli) expression systems. This protein retains structural and functional properties, enabling its use in studying IL-23-specific pathways without interference from IL-12.
IL-23 binds to its receptor (IL-23R) on immune cells, activating JAK-STAT signaling to promote the differentiation and maintenance of Th17 cells. These cells secrete IL-17. IL-22. and other cytokines, driving inflammation and tissue damage in diseases like psoriasis, inflammatory bowel disease (IBD), and ankylosing spondylitis. The IL-23/Th17 axis is a key therapeutic target, with p19-specific inhibitors showing clinical efficacy. For example, monoclonal antibodies targeting IL-23p19 (e.g., risankizumab, guselkumab) are approved for psoriasis and IBD, highlighting the subunit’s therapeutic relevance.
Recombinant IL-23p19 is vital in drug development, serving as an antigen for antibody screening, a tool for receptor-binding studies, or a component in cell-based assays to evaluate inhibitors. It also aids in elucidating IL-23’s role in disease models, such as experimental autoimmune encephalomyelitis (EAE) or colitis. By enabling precise targeting of IL-23-specific pathways, this protein helps reduce off-target effects compared to broader IL-12/IL-23 inhibitors like ustekinumab. Its applications extend to biomarker research, vaccine development, and mechanistic studies of immune dysregulation.
×
